13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001055951
Total reported value
$5.4B
$5.4B
112 檔
27.7%
According to the latest 13F quarterly dataset, Orbimed Advisors LLC managed an equity portfolio of $5.4B at the end of Q4 2024, spanning 112 distinct U.S. exchange-listed positions.
Orbimed Advisors LLC executed strategic sector rebalancing during Q4 2024, establishing 20 new positions while fully exiting 21 holdings and trimming 23 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 8.25% | +1.73% | — | |
| 2 | SVA | Sinovac Biotech Ltd. | Stock-Other | 6.87% | +3.06% | — | |
| 3 | BSX | Boston Scientific CORP | Stock-Healthcare | 5.81% | -1.88% | -3.44% | |
| 4 | LLY | Eli Lilly & Co | Stock-Healthcare | 5.36% | +1.30% | — | |
| 5 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 4.31% | -0.80% | -7.40% | |
| 6 | ELVN | Enliven Therapeutics Inc | Stock-Other | 3.68% | +0.02% | — | |
| 7 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 2.63% | — | +210.41% | |
| 8 | SYK | Stryker CORP | Stock-Healthcare | 2.55% | -0.30% | — | |
| 9 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 2.41% | — | -4.09% | |
| 10 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.40% | -0.44% | -7.24% | |
| 11 | IRON | Disc Medicine Inc | Stock-Other | 2.33% | -0.91% | — | |
| 12 | THC | Tenet Healthcare CORP | Stock-Healthcare | 2.12% | — | +4.48% | |
| 13 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 2.03% | — | +21.20% | |
| 14 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 2.01% | -0.71% | +66.04% | |
| 15 | UPB | Upstream Bio Inc | Stock-Other | 1.93% | -0.32% | — | |
| 16 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 1.80% | -0.12% | — | |
| 17 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.74% | -0.61% | — | |
| 18 | MRK | Merck & Co. Inc. | Stock-Healthcare | 1.70% | -0.05% | -36.94% | |
| 19 | AVBP | Arrivent Biopharma Inc | Stock-Other | 1.66% | +0.53% | — | |
| 20 | BIIB | Biogen Inc | Stock-Healthcare | 1.60% | +0.02% | -37.38% | |
| 21 | ITGR | Integer Holdings CORP | Stock-Healthcare | 1.57% | — | — | |
| 22 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.53% | +0.04% | NEW | |
| 23 | MBX | Mbx Biosciences Inc | Stock-Other | 1.45% | +1.30% | — | |
| 24 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 1.36% | +1.33% | NEW | |
| 25 | NTRA | Natera Inc | Stock-Healthcare | 1.34% | +0.26% | -39.93% | |
| 26 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 1.25% | — | — | |
| 27 | ✓ | Third Harmonic Bio Inc | Stock-Other | 1.22% | — | — | |
| 28 | UHS | Universal Health Services-b | Stock-Healthcare | 1.18% | — | +104.68% | |
| 29 | SIBN | Si-bone Inc | Stock-Other | 1.06% | — | +3.85% | |
| 30 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.05% | -0.04% | -4.86% | |
| 31 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 0.93% | — | -9.75% | |
| 32 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 0.90% | +0.38% | — | |
| 33 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.86% | — | — | |
| 34 | GILD | Gilead Sciences Inc | Stock-Healthcare | 0.85% | -0.17% | EXIT | |
| 35 | CGON | Cg Oncology Inc | Stock-Other | 0.84% | -0.03% | +107.07% | |
| 36 | JANX | Janux Therapeutics Inc | Stock-Other | 0.84% | -0.13% | -39.73% | |
| 37 | EXK | Exact Sciences CORP | Stock-Materials | 0.79% | — | — | |
| 38 | NPCE | Neuropace Inc | Stock-Other | 0.78% | -0.11% | — | |
| 39 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.76% | -0.26% | +4.00% | |
| 40 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 0.76% | -0.16% | — | |
| 41 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 0.69% | +0.88% | NEW | |
| 42 | CMPX | Compass Therapeutics Inc | Stock-Other | 0.67% | -1.03% | — | |
| 43 | XTNT | Xtant Medical Holdings Inc | Stock-Other | 0.67% | — | — | |
| 44 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.67% | — | -2.79% | |
| 45 | VERA | Vera Therapeutics Inc | Stock-Other | 0.65% | — | +9.87% | |
| 46 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.59% | +0.26% | +73.22% | |
| 47 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.49% | -0.07% | EXIT | |
| 48 | VIR | Vir Biotechnology Inc | Stock-Other | 0.49% | — | -9.92% | |
| 49 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 0.46% | +0.11% | -8.24% | |
| 50 | ✓ | Immatics NV | Stock-Other | 0.45% | — | +53.88% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NBIX | Neurocrine Biosciences Inc | +2% | +210.41% | Add |
| 2 | UPB | Upstream Bio Inc | +1.9% | NEW | New buy |
| 3 | EW | Edwards Lifesciences CORP | +1.7% | NEW | New buy |
| 4 | EWTX | Edgewise Therapeutics Inc | +1% | — | Unchanged |
| 5 | BSX | Boston Scientific CORP | +0.8% | -3.44% | Trim |
| 6 | CYTK | Cytokinetics Inc | +0.8% | +106.54% | Add |
| 7 | ALNY | Alnylam Pharmaceuticals Inc | +0.8% | +66.04% | Add |
| 8 | IRON | Disc Medicine Inc | +0.7% | — | Unchanged |
| 9 | XBI | Ss Spdr S&p Biotech ETF | +0.7% | NEW | New buy |
| 10 | SVA | Sinovac Biotech Ltd. | +0.7% | — | Unchanged |
| 11 | GILD | Gilead Sciences Inc | +0.6% | +193.74% | Add |
| 12 | UHS | Universal Health Services-b | +0.5% | +104.68% | Add |
| 13 | ISRG | Intuitive Surgical Inc | +0.4% | -7.40% | Trim |
| 14 | ✓ | Rapt Therapeutics Inc | +0.4% | NEW | New buy |
| 15 | ARGX | Argenx Se - Adr | +0.4% | -7.24% | Trim |
| 16 | CGON | Cg Oncology Inc | +0.4% | +107.07% | Add |
| 17 | AVBP | Arrivent Biopharma Inc | +0.4% | — | Unchanged |
| 18 | NPCE | Neuropace Inc | +0.4% | — | Unchanged |
| 19 | IONS | Ionis Pharmaceuticals Inc | +0.3% | +21.20% | Add |
| 20 | AM6 | Amicus Therapeutics Inc | +0.3% | +300.74% | Add |
| 21 | SYK | Stryker CORP | +0.3% | — | Unchanged |
| 22 | FBRX | Forte Biosciences Inc | +0.3% | NEW | New buy |
| 23 | ITCIEUR | Intra-cellular Therapies Inc | +0.3% | NEW | New buy |
| 24 | ITGR | Integer Holdings CORP | +0.2% | — | Unchanged |
| 25 | CGEM | Cullinan Therapeutics Inc | +0.2% | +81.54% | Add |
| 26 | SIBN | Si-bone Inc | +0.2% | +3.85% | Add |
| 27 | CRDF | Cardiff Oncology Inc | +0.1% | NEW | New buy |
| 28 | PFE | Pfizer Inc | +0.1% | NEW | New buy |
| 29 | VSTM | Verastem Inc | +0.1% | — | Unchanged |
| 30 | GPCR | Structure Therapeutics Inc | +0.1% | +109.02% | Add |
| 31 | SRPT | Sarepta Therapeutics Inc | +0.1% | -4.09% | Trim |
| 32 | INSM | Insmed Inc | +0.1% | NEW | New buy |
| 33 | ✓ | Engene Holdings Inc | +0.1% | NEW | New buy |
| 34 | GERN | Geron CORP | +0.1% | +442.00% | Add |
| 35 | DYN | Dyne Therapeutics Inc | +0.1% | +73.22% | Add |
| 36 | SWTXUSD | Springworks Therapeutics Inc | +0.1% | -9.75% | Trim |
| 37 | VERA | Vera Therapeutics Inc | +0.1% | +9.87% | Add |
| 38 | XENE | Xenon Pharmaceuticals Inc | +0.1% | +4.00% | Add |
| 39 | TYRA | Tyra Biosciences Inc | +0.1% | +91.26% | Add |
| 40 | CRVS | Corvus Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 41 | CRNX | Crinetics Pharmaceuticals In | +0.1% | -4.86% | Trim |
| 42 | CBLL | Ceribell Inc | +0.1% | NEW | New buy |
| 43 | TRAW | Traws Pharma Inc | +0.1% | — | Unchanged |
| 44 | ABCL | Abcellera Biologics Inc | +0.1% | — | Unchanged |
| 45 | RYTM | Rhythm Pharmaceuticals Inc | +0.1% | -8.24% | Trim |
| 46 | IMVT | Immunovant Inc | 0% | NEW | New buy |
| 47 | AKRO | Akero Therapeutics Inc | 0% | NEW | New buy |
| 48 | TNGX | Tango Therapeutics Inc | 0% | NEW | New buy |
| 49 | MIST | Milestone Pharmaceuticals In | 0% | — | Unchanged |
| 50 | MEDP | Medpace Holdings Inc | 0% | — | Unchanged |
According to official SEC Form 13F filings, Orbimed Advisors LLC reported a total U.S. public equity portfolio value of $5.4B across 112 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including EWTX, SVA, BSX) accounted for 27.7% of total reported equity market value during Q4 2024.
Top New Position Initiated
UPB
市值: $93.6M
Top Position Liquidated / Trimmed
AMGN
前期市值: $81.3M
During Q4 2024, Orbimed Advisors LLC's top holdings by market value included EWTX (8.3%)、SVA (6.9%)、BSX (5.8%). The largest single position, EWTX, represented 8.3% of total portfolio value.
In Q4 2024, Orbimed Advisors LLC made 86 total portfolio adjustments, initiating 20 new buys, adding to 22 positions, trimming 23 holdings, and fully liquidating 21 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.